<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04167345</url>
  </required_header>
  <id_info>
    <org_study_id>VX19-814-101</org_study_id>
    <nct_id>NCT04167345</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ Genotype</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-814 in PiZZ
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma functional alpha-1 antitrypsin (AAT) levels</measure>
    <time_frame>From Baseline at Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>From Day 1 up to Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in plasma antigenic AAT levels</measure>
    <time_frame>From Baseline at Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed pre-dose concentration (Ctrough) of VX-814</measure>
    <time_frame>From Day 1 up to Week 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>VX-814</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive different dose levels of VX-814.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will receive placebo matched to VX-814.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-814</intervention_name>
    <description>Tablet for oral administration.</description>
    <arm_group_label>VX-814</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matched to VX-814 for oral administration.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Subjects must have a PiZZ genotype confirmed at screening

          -  Plasma AAT levels indicating severe deficiency at screening

        Key Exclusion Criteria:

          -  History of a medical condition that could negatively impact the ability to complete
             the study

          -  Solid organ, or hematological transplantation or is currently on a transplant list

          -  History of use of gene therapy or RNAi therapy at any time previously

        Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>617-341-6777</phone>
    <email>medicalinfo@vrtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Wells</last_name>
      <phone>205-934-5555</phone>
      <email>jmwells@uab.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patti Smith</last_name>
      <phone>205-934-5555</phone>
      <email>patriciasmith@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Wells</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Tompkins</last_name>
      <phone>916-734-3845</phone>
      <email>dgtompkins@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kris Eliopoulos</last_name>
      <phone>303-270-2622</phone>
      <email>eliopoulosk@njhealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Sandhaus</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida, Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse West</last_name>
      <phone>866-229-6312</phone>
      <email>jesse.west@medicine.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Brantly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group, PA</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bert Kesser</last_name>
      <phone>407-841-1100</phone>
      <phone_ext>118</phone_ext>
      <email>bkesser@cfpulmonary.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Layish</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Wilson</last_name>
      <phone>319-356-2752</phone>
      <email>jeff-wilson@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Teresi</last_name>
      <phone>319-384-7546</phone>
      <email>mary-teresi@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Wilson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heath Latham</last_name>
      <phone>913-588-6046</phone>
    </contact>
    <contact_backup>
      <last_name>Karisa Deculus</last_name>
      <phone>913-945-9295</phone>
      <email>kdeculus@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Heath Latham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blessing Corporate Services, Inc., dba Blessing Health System</name>
      <address>
        <city>Hannibal</city>
        <state>Missouri</state>
        <zip>63401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Humam Farah</last_name>
      <phone>573-231-3766</phone>
      <email>hfarah@hannibalclinic.com</email>
    </contact>
    <contact_backup>
      <last_name>Kimber Steinbeck</last_name>
      <phone>573-231-3261</phone>
      <email>ksteinbeck@hannibalclinic.com</email>
    </contact_backup>
    <investigator>
      <last_name>Humam Farah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Hospitals</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Hardy</last_name>
      <phone>984-974-2971</phone>
      <email>hardykd@live.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Brad Drummond</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Kennedy</last_name>
      <phone>336-713-8559</phone>
      <email>klkenned@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Ortega</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Attaway</last_name>
      <phone>216-317-2051</phone>
      <email>attawaa@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Richard Rice</last_name>
      <phone>216-444-1150</phone>
      <email>ricer@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amy Attaway</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Ruimy</last_name>
      <phone>503-494-0724</phone>
      <email>ruimy@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Alan Barker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlie Strange</last_name>
      <phone>843-792-3174</phone>
      <email>strangec@musc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Millan</last_name>
      <phone>843-792-6280</phone>
      <email>millanr@musc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Charlie Strange</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ather Siddiqi</last_name>
      <phone>713-703-2398</phone>
      <email>ather.siddiqi@renovatioclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Maya Fleyhan</last_name>
      <phone>713-702-2398</phone>
      <email>maya.fleyhan@renovatioclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ather Siddiqi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Couch</last_name>
      <phone>903-877-7037</phone>
      <email>leslie.couch@uthct.edu</email>
    </contact>
    <contact_backup>
      <last_name>Rebekah Hibbard</last_name>
      <phone>903-877-8246</phone>
      <email>Rebekah.hibbard@uthct.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Leslie Couch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospitals &amp; Clinics</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Macy Barrios</last_name>
      <phone>801-581-5811</phone>
      <email>Macy.barrios@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Cheryl Pirozzi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Medical Campus</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Center</name>
      <address>
        <city>Halifax</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inspiration Research Ltd</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pavel Strnad</last_name>
      <phone>00492418035324</phone>
      <email>pstrnad@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Angela Breuer</last_name>
      <phone>00492418085660</phone>
      <email>angbreuer@ukaachen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Pavel Strnad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universit√§tsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Taube</last_name>
      <phone>+49 201 433 4001</phone>
      <email>Christian.Taube@rlk.uk-essen.de</email>
    </contact>
    <contact_backup>
      <last_name>Gina Spangel</last_name>
      <phone>+49 201 433 4893</phone>
      <email>Gina.Spangel@uk-essen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Taube</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Welte</last_name>
      <email>Welte.Tobias@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Natascha Scharf</last_name>
      <email>scharf.natascha@mh-hannover.de</email>
    </contact_backup>
    <investigator>
      <last_name>Tobias Welte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal College of Surgeons in Ireland Clinical Research Centre, Beaumont Hospital</name>
      <address>
        <city>Beaumont</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 15, 2019</study_first_submitted>
  <study_first_submitted_qc>November 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

